Abstract
Abstract: INTRODUCTION: Mucormycosis, or zygomycosis, is an aggressive fungal infection caused by Mucorales, posing a significant threat, particularly to immunocompromised individuals. Its incidence has surged in the context of the COVID-19 pandemic, necessitating a deeper understanding of its management strategies. MATERIALS AND METHODS: This retrospective cross-sectional study analyzed prescription patterns for post-COVID-19 mucormycosis in a tertiary care hospital. Medical records of 108 patients diagnosed with post-COVID-19 mucormycosis were reviewed to extract relevant data. RESULTS: The study revealed notable patterns in prescription management, including a male predominance (78.3%) and a mean age of 52.41 years. Diabetes mellitus was prevalent (95%), emphasizing its association with mucormycosis. Antifungal therapy, primarily posaconazole (95%), and adjunctive treatments varied. Surgical intervention, particularly debridement (70%), was crucial. Analgesic therapy, notably diclofenac (52%), and other medications were commonly prescribed, reflecting the complex health-care needs of mucormycosis patients. CONCLUSION: The study provides valuable insights into prescription patterns in post-COVID-19 mucormycosis, emphasizing the need for tailored approaches to optimize outcomes in this vulnerable patient population. Understanding prescription patterns for post-COVID-19 mucormycosis is vital for guiding clinical decision-making and optimizing treatment strategies in this vulnerable patient population. Further research is warranted to address limitations and enhance patient care and outcomes.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call